【Intro】Formosa Pharmaceuticals, Inc.

Formosa Pharmaceuticals, Inc.

Company Introduction

台新藥股份有限公司總部位於台灣,聯盟夥伴遍布美國與亞洲。專利奈米顆粒藥物傳輸平台(APNT)可提高難溶性API的溶離度和生物可用度,所開發出的APP13007已在美國展開針對白內障手術後炎症和疼痛的臨床三期研究,同時已將中國、香港和澳門地區授權與遠大醫藥健康控股有限公司。我們持續歡迎關於 APP13007 於其他區域授權的洽詢,或是其他小分子API於APNT平台的合作開發機會。
TSY-0110 (Kadcyla ADC)生物相似藥)現進入臨床前開發後期,中間體抗體由夥伴台康生技提供,從原料藥液到成品都自主完成生產,歡迎任何區域和全球市場共同開發或授權的機會。
Formosa Pharmaceuticals is a preclinical and early-clinical stage biotech with assets in ophthalmology, oncology, and anti-infectives.  Based in Taipei, Taiwan, Formosa Pharmaceuticals has a network of global partners and senior executives with international drug discovery and management experience.  TSY0110, a biosimilar of ado-trastuzumab emtansine, is under development and available for partnering/licensing.  APP13007, our lead asset for the treatment of post-surgical ocular pain and inflammation, has initiated Phase 3 studies in the United States, and expects to be approved in 2023.  Our proprietary APNT drug delivery formulation platform, from which APP13007 was developed, is available for licensing, CDMO services, or co-development.

Brief description of main products or services 

Formosa Pharmaceuticals offers the following assets for partnering, co-development, or regional licensing:
  • TSY-0110
    • Biosimilar of the antibody-drug conjugate, Kadcyla® for metastatic breast cancer
    • Planned Phase 1 clinical trials (EU) in 2022
    • Full-range manufacturing from payload-linker, bioconjugation, and fill-finish with partner, Formosa Laboratories
  • APP13007
    • Potent steroid-based eyedrop for Inflammation and Pain after Ocular Surgery
    • Phase 3 clinical studies ongoing in United States
    • Anticipated approval in 2023
  • APP13002
    • Antibiotic-based eyedrop for infectious eye diseases
    • Future potential indication in Blepharitis
    • Potential as monotherapy or combination
  • APNT nanoparticle formulation platform
    • Tailored for APIs with poor solubility, the APNT platform enhances the dissolution and distribution, thereby improving bioavailability.
    • Applicable to topical, inhaler, and oral administration routes
    • The APNT platform’s characteristics and advantages:
      • Reliable and tunable particle reduction down to sub-100 micron size
      • Stable particle size post-formulation
      • Lower contamination and removable excipients to enable higher concentration
      • Amenable to aseptic filtration
      • Strong patent protection
  • MPT0E028
    • Novel small-molecule HDAC inhibitor for the treatment of solid tumors and lung fibrosis
    • Completed Phase 1 in Taiwan
    • Out-licensed (non-exclusive) to Anbogen Therapeutics (Taiwan) and Joseah Bio (Korea)